drugset / Trial / NCT07318870

Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring

NCT07318870

Phase 2 Not yet recruiting 600 enrolled Fondation Ophtalmologique Adolphe de Rothschild
RandomizedParallel-groupTriple-blindTreatment

Summary

ProbCluster trial aims at making the proof of concept of antiseizure efficacy of the old antigout PBN in SC, in which Panx1 involvement is relevant on SC pathophysiology and in which efficient therapies are still lacking. The trial will be performed on patients with focal epilepsy in presurgical evaluation undergoing video-EEG monitoring, a setting characterized by a high risk of SC and an efficient video-EEG monitoring of seizures, reducing the risk of erroneous report based on patient home assessment. PBN is a good candidate for a repurposing in epilepsy, due to its brain penetration allowing Panx1 in situ blockade and of its good security profile. The repurposing process allows a faster, safer and cheaper development.

Timeline

Start
2026-01
Primary completion
2029-02
Completion
2029-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Probenecid Small molecule 1 g Oral
Subject Probenecid Small molecule 2 g Oral
Subject Probenecid Small molecule 3 g Oral

Indications